L. Hughes-Davies

发表

Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome

Luke Hughes-Davies, Charles Theillet, Tony Kouzarides, 2004, Clinical Cancer Research.

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.

S. Pinder, H. Earl, D. Rea, 2016, Journal of the National Cancer Institute.

Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer

J. Donovan, S. Pinder, D. Rea, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial

S. Pinder, A. Makris, J. Bartlett, 2017, British Journal of Cancer.

OPTIMA: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

J. Donovan, S. Pinder, A. Makris, 2016 .

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.

John M S Bartlett, Christopher McCabe, Nigel Stallard, 2016, Health technology assessment.

DNA methyltransferase Dnmt1 associates with histone deacetylase activity

Luke Hughes-Davies, François Fuks, Tony Kouzarides, 2000, Nature Genetics.

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial

C. Caldas, E. Provenzano, J. Abraham, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2015, The Lancet. Oncology.

Suramin increases p53 protein levels but does not activate the p53-dependent G1 checkpoint.

C. N. Coleman, C. Coleman, S. Park, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

The precarious path to diagnostic accuracy: the Ontario hormone receptor guideline.

L. Hughes-Davies, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

Stage IA-IIB Hodgkin's disease: management and outcome of extensive thoracic involvement.

B. Silver, N. Tarbell, L. Shulman, 1997, International journal of radiation oncology, biology, physics.

Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR).

C. Caldas, E. Provenzano, H. Earl, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

University of Birmingham Strategies to improve recruitment to a de-escalation trial

L. Hughes-Davies, A. Marshall, J. Dunn, 2020 .

The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase

T. Kouzarides, J. Milner, L. Hughes-Davies, 2000, Oncogene.

Cdk2 kinase phosphorylates serine 315 of human p53 in vitro.

S. Park, B. Price, L. Hughes-Davies, 1995, Oncogene.

Transcriptional activation functions in BRCA2

Luke Hughes-Davies, Tony Kouzarides, B. Ponder, 1997, Nature.

Nerve growth factor/nuclear factor-κB pathway as a therapeutic target in breast cancer

A. Naderi, L. Hughes-Davies, 2009, Journal of Cancer Research and Clinical Oncology.

Definition of Tumor Bed Boost in Oncoplastic Breast Surgery: An Understanding and Approach.

L. Hughes-Davies, A. Agrawal, E. Garreffa, 2020, Clinical breast cancer.

Serum cardiac troponin T levels during treatment of early-stage breast cancer.

J. Harris, L. Hughes-Davies, J. Rescigno, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.

E. Provenzano, J. Abraham, H. Earl, 2017 .

Barriers to protocol-led early discharge of low-risk febrile neutropenia patients.

L. Hughes-Davies, E. Day, S. Kim, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Occult alveolar haemorrhage in bronchopulmonary Kaposi's sarcoma.

R. Miller, L. Hughes-Davies, G. Kocjan, 1992, Journal of clinical pathology.

Severe adverse cutaneous reactions to drugs.

L. Hughes-Davies, L Hughes-Davies, 1995, The New England journal of medicine.

Fournier's gangrene: a hazard of chemotherapy in AIDS.

L. Hughes-Davies, M. Spittle, P. Murray, 1991, Clinical oncology (Royal College of Radiologists (Great Britain)).

The Tudor domain 'Royal Family': Tudor, plant Agenet, Chromo, PWWP and MBT domains.

Sebastian Maurer-Stroh, Frank Eisenhaber, Luke Hughes-Davies, 2003, Trends in biochemical sciences.

EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer

Luke Hughes-Davies, Carlos Caldas, David S Yu, 2003, Cell.

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.

R. Laing, C. Caldas, E. Provenzano, 2014, The Lancet. Oncology.

Tamoxifen: the drug that came in from the cold

L. Hughes-Davies, G C Wishart, L Hughes-Davies, 2009, British Journal of Cancer.

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

C. Caldas, J. Abraham, H. Earl, 2018 .

Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.

J. Donovan, S. Pinder, H. Earl, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

C. Caldas, E. Provenzano, J. Abraham, 2020, Health technology assessment.

The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation

E. Provenzano, H. Earl, D. Rea, 2019, Journal of clinical epidemiology.

Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.

H. Earl, D. Rea, A. Makris, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Technical modifications required to treat cervical chemodactomas with stereotactic radiosurgery.

H. Kooy, E. Alexander, J. Loeffler, 1994, Surgical neurology.

Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.

R. Hesketh, A. Philpott, L. Hughes-Davies, 2001, Cancer research.

BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer

A. Naderi, L. Hughes-Davies, Ji Liu, 2010, Molecular Cancer.

Fluorouracil and folinic acid in colon cancer

S. Marsoni, L. Hughes-Davies, J. Rescigno, 1995, The Lancet.

A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.

Luke Hughes-Davies, A. Naderi, L. Hughes-Davies, 2008, Neoplasia.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

C. Caldas, E. Provenzano, J. Abraham, 2019, The Lancet.

versus 12 months of adjuvant trastuzumab for HER 2-positive early breast cancer ( PERSEPHONE ) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

C. Caldas, E. Provenzano, J. Abraham, 2019 .

Trastuzumab-associated cardiac events in the Persephone trial

J. Abraham, H. Earl, D. Miles, 2016, British Journal of Cancer.

Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

C. Caldas, E. Provenzano, J. Abraham, 2017, Modern Pathology.

Radiosensitivity in AIDS patients

L. Hughes-Davies, M. Spittle, T. Young, 1991, The Lancet.

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

C. Caldas, J. Abraham, H. Earl, 2020, Clinics in oncology.

The International Core Literature Consensus (ICLC): an Alternative Curriculum for Oncologists

R. Jagsi, L. Hughes-Davies, Shilpen A. Patel, 2011, Journal of Cancer Education.

Metastatic cerebral lymphoma.

R. Miller, L. Hughes-Davies, S. Lucas, 1991, Genitourinary medicine.

Binding of EMSY to HP1β: implications for recruitment of HP1β and BS69

L. Itzhaki, T. Kouzarides, C. Ekblad, 2005 .

Binding of EMSY to HP1beta: implications for recruitment of HP1beta and BS69.

L. Itzhaki, T. Kouzarides, C. Ekblad, 2005, EMBO reports.

An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment

R. Peto, J. Donovan, T. Powles, 2018, Journal of clinical epidemiology.

Consolidated criteria for reporting qualitative research guidelines

J. Donovan, S. Pinder, A. Makris, 2016 .

Training the oncologists of the future.

L. Hughes-Davies, J. Barrett, 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

Abstract PD2-3: ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer

C. Caldas, E. Provenzano, J. Abraham, 2015 .

Abstract P4-11-07: Comparison of multiparameter tests in the UK OPTIMA-Prelim trial

J. Donovan, S. Pinder, A. Makris, 2015 .

C. Caldas, E. Provenzano, J. Abraham, 2015, The Lancet. Oncology.

Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No.

L. Hughes-Davies, F. Macbeth, 2021, Clinics in oncology.

Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals.

N. Shah, L. Hughes-Davies, A. Doble, 2017, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Parametrial interstitial brachytherapy for advanced or recurrent pelvic malignancy: the Harvard/Stanford experience.

L. Hughes-Davies, D. Kapp, B. Silver, 1995, Gynecologic oncology.

Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.

B. Kiely, D. Rea, B. Naume, 2021 .

OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.

S. Pinder, H. Earl, D. Rea, 2016 .

ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer-Primary endpoint, pathological complete response (pCR)

C. Caldas, E. Provenzano, J. Abraham, 2014 .